Development of targeted therapies for triple-negative breast cancer: can we harness tumor heterogeneity to improve patient outcomes?
How can we improve survival from breast cancer in developing countries?
A possible target for hormone therapy-induced breast cancers
Mammography: is every 2 years enough in most women?
Forty nine steps closer to the genetic basis of breast cancer risk
Molecular diversity between triple-negative and basal-like breast cancer
Bhola, NE, Balko JM, Dugger TC et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123, 1348–1358 (2013).
Pal B, Bouras T, Shi W et al. Global changes in the mammary epigenome are induced by hormonal cues and coordinated EZH2. Cell Rep. 3, 411–426 (2013).
Yu M, Bardia A, Wittner BS et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584 (2013).
Barbashina V, Corben AD, Akram M et al. Mucinous micropapillary carcinoma of the breast: an aggressive counterpart to conventional pure mucinous tumors. Hum. Pathol. doi:10.1016/j.humpath.2013.01.003 (2013) (Epub ahead of print).
Ask the Experts: Accelerated partial breast irradiation: the future of radiation therapy for breast cancer?
Interview: Advancing translational research in breast cancer
Conference Scene: Which way to go in the increasingly complex era of breast cancer heterogeneity
Role of the breast cancer surgeon in the personalized era
Overview of nanoparticle albumin-bound paclitaxel in metastatic breast cancer
Immune aspects of the breast tumor microenvironment
Ductal carcinoma in situ : how should we treat it?
Acknowledgements